This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…
Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…
The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…
“IP rights are usually the true asset that a start-up company has.” Dr. Philipp Marchand talks with BaseLaunch and takes some questions from an audience…
The selection committee has chosen 15 promising projects for Phase I. The projects all focus on developing innovative technologies to dramatically change patient outcomes in a variety…